Progressive supranuclear palsy;Paralisia Supranuclear Progressiva: Conceitos Atuais

Arquivos de Neuro-Psiquiatria

Volumn 68, Issue 6, 2010, Pages 938-946

  Barsottini, Orlando Graziani Povoas ^a   Felício, André Carvalho ^a   de Aquino, Camila Catherine Henriques ^a   Pedroso, José Luiz ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Atypical parkinsonism; Progressive supranuclear palsy; Tauopathy

Indexed keywords

4 AMINOBUTYRIC ACID; 5 HYDROXYTRYPTOPHAN; BOTULINUM TOXIN; DOPAMINE TRANSPORTER; EFAROXAN; GABAPENTIN; GLYCOGEN SYNTHASE KINASE 3; IDAZOXAN; LEUCINE RICH REPEAT KINASE 2; LEVODOPA; METHYSERGIDE; MUSCARINIC AGENT; RILUZOLE; TAU PROTEIN; TRICYCLIC ANTIDEPRESSANT AGENT; ZOLPIDEM;

AKINESIA; ALZHEIMER DISEASE; APRAXIA; AUTOSOMAL DOMINANT DISORDER; BRAIN BLOOD FLOW; BRAIN DEPTH STIMULATION; CEREBROSPINAL FLUID; CERVICAL DYSTONIA; CLINICAL FEATURE; COGNITIVE DEFECT; CORPUS STRIATUM; DENTATE NUCLEUS; DISEASE DURATION; DYSTONIA; EYE MOVEMENT; GAIT DISORDER; GENE MUTATION; GENETICS; GLOBUS PALLIDUS; HUMAN; MEDULLA OBLONGATA; MOLECULAR IMAGING; NEUROFIBRILLARY TANGLE; NEUROIMAGING; NEUROPIL THREAD; NEUROPROTECTION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OCULOMOTOR NUCLEUS; OPHTHALMOPLEGIA; PALLIATIVE THERAPY; PARKINSONISM; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; PROGRESSIVE NONFLUENT APHASIA; PROGRESSIVE SUPRANUCLEAR PALSY; RED NUCLEUS; REVIEW; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SUBSTANTIA NIGRA; SURVIVAL; TAUOPATHY; TEGMENTUM; TREATMENT RESPONSE;

EID: 79251591682     PISSN: 0004282X     EISSN: 16784227     Source Type: Journal    
DOI: 10.1590/S0004-282X2010000600020     Document Type: Review

References (52)

1. Steele JC, Richardson JC, Olszewski J. Progressive supranuclear palsy. A heterogeneous degeneration involving the brain stem, basal ganglia and cerebellum with vertical gaze and pseudobulbar palsy, nuchal dystonia and dementia. Arch Neurol 1964;10:333-359.
2. Santacruz P, Uttl B, Litvan I, Grafman J. Progressive supranuclear palsy: a survey of the disease course. Neurology 1998;50:1637-1647.
3. Lubarsky M, Juncos JL. Progressive supranuclear palsy: a current review. The Neurologist 2008;14:79-88.
4. Morris HR, Wood NW, Lees AJ. Progressive supranuclear palsy (Steele-Richardson-Olszewski disease). Postgrad Med J 1999;75:579-584.
5. Rajput A, Dickson DW, Robinson CA, et al. Parkinsonism, LrrK2 G2019S, and tau neuropathology. Neurology 2006;67:1506-1508.
6. Santos-Rebouças CB, Abdalla CB, Baldi FJR, et al. Co-occurrence of sporadic parkinsonism and late-onset Alzheimer's disease in a Brazilian male with the LRRK2 p.G2019S mutation. Genet Test 2008;2:471-473.
7. Ludolph AC, Kassubek J, Landwehrmeyer BG, et al. Tauopathies with parkinsonism: clinical spectrum, neuropathologic basis, biological markers and treatment options. Eur J Neurol 2009;16:297-309.
8. Pastor P. Familial neurodegeneration in progressive supranuclear palsy. More frequent than expected? Neurology 2009;73:86-87.
9. Ros R, Gomez Garre P, Hirano M, et al. Genetic linkage of autosomal dominant progressive supranuclear palsy to 1q31.1. Ann Neurol 2005;57: 634-641.
10. Williams D, Lees AJ. Progressive supranuclear palsy: clinicopathological concepts and diagnostic challenges. Lancet Neurol 2009;8:270-279.
11. Rohrer JD, Paviour D, Bronstein AM, et al. Progressive supranuclear palsy syndrome presenting as progressive nonfluent aphasia: a neuropsychological and neuroimaging analysis. Mov Disord 2010; in press.
12. Kanazawa M, Shimohata T, Toyoshima Y, et al. Cerebellar involvement in progressive supranuclear palsy: a clinicopathological study. Mov Disord 2009;24:1312-1218.
13. Litvan I, Agid Y, Calne D, et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP International Workshop. Neurology 1996;47:1-9.
14. Borroni B, Malinverno M, Gardoni F, et al. Tau forms in CSF as a reliable biomarker for progressive supranuclear palsy. Neurology 2008;71:1796-1803.
15. Osaki Y, Ben-Shlomo Y, Lees AJ, et al. Accuracy of clinical diagnosis of progressive supranuclear palsy. Mov Disord 2004;19:181-189.
16. Sakamoto R, Tsuchiya K, Mimura M. Clinical heterogeneity in progressive supranuclear palsy: problems of clinical diagnostic criteria of NINDS-SPSP in a retrospective study of seven Japanese autopsy cases. Neuropathology 2009;29:1-12.
17. Williams DR, Holton JL, Strand C, et al. Pathological tau burden and distribution distinguishes progressive supranuclear palsy-parkinsonism from Richardson's syndrome. Brain 2007;130:1566-1576.
18. Seppi K, Schocke MF. An update on conventional and advanced magnetic resonance imaging techniques in the differential diagnosis of neurodegenerative parkinsonism. Curr Opin Neurol 2005;18:370-375.
19. Newman EJ, Breen K, Patterson J, et al. Accuracy of Parkinson's disease diagnosis in 610 general practice patients in the West of Scotland. Mov Disord 2009;24:2379-2385.
20. Seppi K. MRI for the differential diagnosis of neurodegenerative parkinsonism in clinical practice. Parkinsonism Relat Disord 2007;3(Suppl):S400-S405.
21. Duchesne S, Rolland Y, Vérin M. Automated computer differential classification in Parkinsonian syndromes via pattern analysis on MRI. Acad Radiol 2009;16:61-70.
22. Cosottini M, Ceravolo R, Faggioni L, et al. Assessment of midbrain atrophy in patients with progressive supranuclear palsy with routine magnetic resonance imaging. Acta Neurol Scand 2007;116:37-42.
23. Barsottini OG, Ferraz HB, Maia AC Jr, et al. Differentiation of Parkinson's disease and progressive supranuclear palsy with magnetic resonance imaging: the first Brazilian experience. Parkinsonism Relat Disord 2007;13:389-393.
24. Felicio AC, Shih MC, Godeiro-Junior C, et al. Molecular imaging studies in Parkinson disease: reducing diagnostic uncertainty. Neurologist 2009; 15:6-16.
25. Varrone A, Pagani M, Salvatore E, et al. Identification by [99mTc]ECD SPECT of anterior cingulate hypoperfusion in progressive supranuclear palsy, in comparison with Parkinson's disease. Eur J Nucl Med Mol Imaging 2007; 34:1071-1081.
26. Eckert T, Barnes A, Dhawan V, et al. FDG PET in the differential diagnosis of parkinsonian disorders. Neuroimage 2005;26:912-21.
27. Park HK, Kim JS, Im KC, et al. Functional brain imaging in pure akinesia with gait freezing: [18F] FDG PET and [18F] FP-CIT PET analyses. Mov Disord 2009;24:237-245.
28. Kim YJ, Ichise M, Ballinger JR, et al. Combination of dopamine transporter and D2 receptor SPECT in the diagnostic evaluation of PD, MSA, and PSP. Mov Disord 2002;17:303-312.
29. Antonini A, Benti R, De Notaris R, et al. 123I-Ioflupane/SPECT binding to striatal dopamine transporter (DAT) uptake in patients with Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. Neurol Sci 2003;24:149-50.
30. Litvan I, Bhatia KA, Burn DJ, et al. Movement Disorder Society Scientific Issues Committee Report. SIC task force appraisal of clinical diagnostic criteria for parkinsonian disorders. Mov Disord 2003;18:467-486.
31. Lang AE. Treatment of progressive supranuclear palsy and corticobasal degeneration. Mov Disord 2005;20:S83-S91.
32. Williams DR, de Silva R, Paviour DC, et al. Characteristics of two distinct clinical phenotypes in pathologically proven progressive supranuclear palsy: Richardson's syndrome and PSP-parkinsonism. Brain 2005;128:1247-1258.
33. Constantinescu R, Richard I, Kurlan R. Levodopa responsiveness in disorders with parkinsonism: a review of literature. Mov Disord 2007;22:2141-2148.
34. Kompoliti K, Goetz CG, Litvan I. Pharmacological therapy in progressive supranuclear palsy. Arch Neurol 1998;55:1099-1102.
35. Weiner WJ, Minagar A, Shulman LM. Pramipexole in progressive supranuclear palsy. Neurology 1999;52:873-874.
36. Burn DJ, Warren NM. Toward future therapies in progressive supranuclear palsy. Mov Disord 2005;20:S92-S98.
37. Liepelt I, Gaenslen A, Godau J, et al. Rivastigmine for the treatment of dementia in patients with progressive supranuclear palsy: clinical observations as a basis for power calculations and safety analysis. Alzheimers Dement 2010;6:70-74.
38. Ghika J, Tennis M, Hoffman E, et al. Idazoxan treatment in progressive supranuclear palsy. Neurology 1991;41:986-991.
39. Rascol O, Sieradzan K, Peyro SP, et al. Efaroxan, an alpha-2 antagonist, in the treatment of progressive supranuclear palsy. Mov Disord 1998;13: 673-676.
40. Newman GC. Treatment of progressive supranuclear palsy with tricyclic antidepressants. Neurology 1985;35:1189-1193.
41. Nieforth KA, Golbe LI. Retrospective study of drug response in 87 patients with progressive supranuclear palsy. Clin Neuropharmacol 1993;16: 338-346.
42. Tamai S, Almeida OP. Nortriptyline for the treatment of depression in progressive supranuclear palsy. J Am Geriatr Soc 1997;45:1033-1034.
43. Cotter C, Armytage T, Crimmins D. The use of zolpidem in the treatment of progressive supranuclear palsy. J Clin Neurosci 2010; in press.
44. Mayr B, Bonelli RM, Niederwieser G, et al. Zolpidem in progressive supranuclear palsy. Eur J Neurol 2002;9:184-185.
45. Poujois A, Vidailhet M, Trocello JM, Bourdain F, Gaymard B, Rivaud-Péchoux S. Effect of gabapentin on oculomotor control and parkinsonism in patients with progressive supranuclear palsy. Eur J Neurol 2007;14:1060-1062.
46. Godeiro-Junior C, Felício AC, Barsottini OG, et al. Clinical features of dystonia in atypical parkinsonism. Arq Neuropsiquiatr 2008;66:800-804.
47. Bensimon G, Ludolph A, Agid Y. Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study. Brain 2009;132: 156-171.
48. Mudher A, Shepherd D, Newman TA, et al. GSK-3beta inhibition reverses axonal transport defects and behavioural phenotypes in Drosophila. Mol Psychiatry 2004;9:522-530.
49. Engel T, Hernandez F, Avila J, Lucas JJ. Full reversal of Alzheimer's disease-like phenotype in a mouse model with conditional overexpression of glycogen synthase kinase-3. J Neurosci 2006;26:5083-5090.
50. Engel T, Goni-Oliver P, Lucas JJ, Avila J, Hernandez F. Chronic lithium administration to FTDP-17 tau and GSK-3b overexpressing mice prevents tau hyperphosphorylation and neurofibrillary tangle formation, but preformed neurofibrillary tangles do not revert. J Neurochem 2006;99:1445-1455.
51. Bergmann KJ, Salak VL. Subthalamic stimulation improves levodopa responsive symptoms in a case of progressive supranuclear palsy. Parkinsonism Relat Disord 2008;14:348-352.
52. Litvan I. Diagnosis and management of progressive supranuclear palsy. Semin Neurol 2001;21:41-48.